Abstract Details

Title Preclinical Safety of AVI-4658, a Phosphorodiamidate Morpholino Oligomer (PMO) Being Developed To Skip Exon 51 in Duchenne Muscular Dystrophy

Topic Muscle Disease/Neuromuscular Junction

Presentation(s) (-)

Poster/Presentation
Number 044

Objective

Background

Design/Methods

Results

Conclusions

Authors/Disclosures
Peter Sazani, PhD	No disclosure on file
Stephen B. Shrewsbury, MD (Impel Pharmaceuticals)	Dr. Shrewsbury has received personal compensation for serving as an employee of Impel NeuroPharma. Dr. Shrewsbury has received stock or an ownership interest from Impel NeuroPharma.
Melissa Murray, PhD (Mayo Clinic)	Dr. Murray has received personal compensation in the range of $10,000-$49,999 for serving as a Consultant for Avid Radiopharmaceuticals. The institution of Dr. Murray has received research support from National Institute on Aging. The institution of Dr. Murray has received research support from Alzheimer's Association. The institution of Dr. Murray has received research support from Chan Zuckerberg Initiative.

��ɫ��